DEF: Prothena Schedules 2026 AGM, Board & Executive Pay Votes

Prothena Corporation plc announces its 2026 Annual General Meeting to address director elections, auditor ratification, and executive compensation.

Summary

• The Annual General Meeting (AGM) is scheduled for Thursday, May 14, 2026, at 4:00 p.m. local time in Dublin, Ireland.
• Shareholders will vote on the election of Shane M. Cooke and Dennis J. Selkoe as directors, to hold office until no later than the annual general meeting in 2029.
• Shareholders will ratify, in a non-binding vote, the appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 and authorize the Board to approve their remuneration.
• A non-binding advisory vote will be held on the compensation of the named executive officers for fiscal year 2025.
• The Board of Directors unanimously recommends voting FOR all proposals.
• As of the Record Date, March 2, 2026, there were 53,832,982 ordinary shares issued and outstanding.
• The Phase 3 AFFIRM-AL clinical trial for birtamimab in Mayo Stage IV AL amyloidosis was completed in May 2025 but did not meet its primary or secondary endpoints, leading to the discontinuation of development and an approximate 63% workforce reduction in June 2025.
• The Phase 1 ASCENT clinical program for PRX012 in early Alzheimer's disease was completed in 2025, demonstrating robust plaque clearance but with non-competitive rates of ARIA-E; PRX012-TfR is now in preclinical studies.
• Partnered programs advanced significantly in 2025: Roche initiated the Phase 3 PARAISO clinical trial for prasinezumab (Parkinson's disease), expected to complete in 2029. Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial for coramitug (ATTR cardiomyopathy), expected to complete in 2029, after presenting positive Phase 2 results in November 2025. Bristol Myers Squibb (BMS) completed enrollment for the Phase 2 TargetTau-1 clinical trial for BMS-986446 (Alzheimer's disease), expected to complete in 1H 2027, and the drug received Fast Track designation from the U.S. FDA. A Phase 1 trial for PRX019 (neurodegenerative diseases) is ongoing and on track for completion in 2026.
• Cash used in operating and investing activities for fiscal year 2025 was $163.7 million, which was favorable to the guidance range of $170 to $178 million.
• Finished fiscal year 2025 with $308.4 million in cash, cash equivalents, and restricted cash, exceeding guidance of $298.0 million.
• Executive compensation for fiscal year 2025 included base salary increases for named executive officers (Dr. Kinney 6.4%, Dr. Zago 4.6%, Mr. Smith and Dr. Swanson 4.0%, Mr. Nguyen 3.5%).
• Annual bonuses for named executive officers were paid at 100% of target for fiscal year 2025, based on 100% achievement of corporate objectives.
• One-time RSU retention awards with a three-year vesting schedule were granted to named executive officers in July 2025 following the birtamimab program discontinuation and reorganization.
• The Chief Executive Officer-to-median employee pay ratio for 2025 was approximately 14 times ($5,896,045 for the CEO vs. $417,917 for the median employee).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but predominantly negative filing due to the significant clinical trial failure of birtamimab, the resulting workforce reduction, and the concerning safety profile of PRX012, despite strong cash management and progress in partnered programs.

Positives

• Cash used in operating and investing activities for fiscal year 2025 was $163.7 million, which was favorable to the guidance range of $170 to $178 million.
• Ended fiscal year 2025 with $308.4 million in cash, cash equivalents, and restricted cash, exceeding guidance of $298.0 million, providing a solid financial foundation.
• Partnered programs show significant advances: Roche initiated Phase 3 PARAISO for prasinezumab (Parkinson's disease), and Novo Nordisk initiated Phase 3 CLEOPATTRA for coramitug (ATTR cardiomyopathy) with positive Phase 2 results.
• BMS-986446 (Alzheimer's disease) completed Phase 2 enrollment and received Fast Track designation from the U.S. FDA.
• PRX019 Phase 1 trial is ongoing and on track for completion in 2026.
• TDP-43 CYTOPE preclinical data demonstrates potential in ALS and other proteinopathies.
• Executive compensation annual bonuses were paid at 100% of target for fiscal year 2025, reflecting 100% achievement of corporate objectives.

Negatives

• The Phase 3 AFFIRM-AL clinical trial for birtamimab did not meet its primary or secondary endpoints, leading to the discontinuation of its development.
• A corporate restructuring in June 2025 included an approximate 63% reduction in workforce due to the birtamimab trial failure.
• The Phase 1 ASCENT clinical program for PRX012, while showing robust plaque clearance, was associated with non-competitive rates of ARIA-E, leading to a shift to preclinical development for PRX012-TfR.
• Shareholder approval for 2024 executive compensation was 76%, well below the 94% average support from the prior five annual general meetings, indicating some shareholder dissatisfaction.
• Net income (loss) for fiscal year 2025 decreased to $(244,092,000) from $(122,310,000) in 2024.

Risks

• Clinical trial failures, as demonstrated by the discontinuation of birtamimab development after Phase 3 failure, are inherent risks in drug development.
• Adverse event rates, such as PRX012's non-competitive rates of ARIA-E, could hinder future development or market potential for drug candidates.
• Talent retention challenges may arise following the corporate restructuring and workforce reduction, despite one-time retention awards.
• Regulatory hurdles and the lengthy approval processes for new drugs pose ongoing risks, even with Fast Track designations.
• The highly competitive environment for talent in the biotechnology industry could impact the ability to attract and retain skilled personnel.
• Shareholder dissatisfaction with executive compensation, as indicated by lower Say-on-Pay approval, could lead to governance challenges or reputational damage.
• Continued net losses and reliance on cash balance management highlight ongoing financial risks inherent in a late-stage clinical company without commercialized products.

Future Outlook

The company is continuing to advance its discovery and clinical programs, leveraging a solid financial foundation. Partnered programs like prasinezumab and coramitug are progressing into Phase 3 trials with primary completion expected in 2029, and BMS-986446 is in Phase 2 with primary completion expected in 1H 2027. The preclinical program PRX012-TfR is being developed while exploring potential partnership opportunities, and PRX019's Phase 1 trial is on track for completion in 2026. Roche has stated that prasinezumab has peak sales potential greater than $3.5 billion (unadjusted).

Management Comments

• Our executive compensation programs are designed to align executive pay outcomes with the Company's performance.
• We believe that our named executive officers fiscal year 2025 compensation was aligned with the Company's performance for the year and with the Company's go-forward strategy.
• We are a late-stage clinical company with a robust pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases.
• We carefully managed our capital. While progressing all of our development programs described above, our cash used in operating and investing activities was $163.7 million, which was favorable to our guidance range of $170 to $178 million. We finished fiscal year 2025 with $308.4 million in cash, cash equivalents, and restricted cash, which exceeded our guidance of $298.0 million, providing a solid financial foundation for continuing to advance the Company's discovery and clinical programs.
• The Committee believes that compensation decisions are complex and require a deliberate review of Company performance, peer compensation levels, experience and impact of individual executive officers, and individual performance.

Industry Context

StockSavvy.ai notes that Prothena's strategic shift following the birtamimab trial failure and subsequent workforce reduction reflects a common challenge in the biopharmaceutical industry, where high-risk, high-reward drug development often leads to significant restructuring when programs fail. The company's pivot to focus on its robust partnered pipeline, including Phase 3 trials for Parkinson's and ATTR cardiomyopathy, aligns with a trend of de-risking through collaborations, a strategy often employed by smaller biotech firms to leverage larger pharmaceutical partners' resources and expertise. The continued investment in preclinical programs like PRX012-TfR and TDP-43 CYTOPE, alongside exploring partnership opportunities, indicates a balanced approach to innovation and capital management in a competitive landscape.

Comparison to Industry Standards

• Prothena's market capitalization of approximately $1.2 billion at the time of peer group approval placed it at the 26th percentile of its peer group, which ranged from $480 million to $8.0 billion, suggesting the company is on the smaller side compared to its selected peers.
• The company's research and development expense was at approximately the 52nd percentile of its peer group's range of $40 million to $700 million, indicating a moderate R&D investment relative to its peers.
• Cash and short-term investments were at approximately the 46th percentile of the peer group's range of $140 million to $1.0 billion, suggesting a relatively healthy cash position within its peer group.
• The CEO-to-median employee pay ratio of 14 times is lower than the average S&P 500 CEO pay ratio, which often exceeds 200-300 times, but comparisons should be made within the specific biotechnology industry context.
• The 76% shareholder approval for 2024 executive compensation is below the average for S&P 500 companies (typically 85-90%), and significantly lower than Prothena's own prior five-year average of 94%, indicating a potential disconnect with shareholders on compensation practices.

Management Changes

Corporate Governance

Related Party Transactions

• There have been no Related Person Transactions to report since January 1, 2025.

Stakeholder Impact

• Shareholders are directly impacted by the outcome of clinical trials, which affects share price and future value. The 63% workforce reduction could be seen positively for cost savings or negatively for morale/future innovation capacity.
• Employees are directly impacted by the 63% workforce reduction in June 2025. Remaining employees received one-time retention awards.
• Customers/Patients may be impacted by the development of new therapeutics for neurodegenerative and rare amyloid diseases, particularly from partnered programs. The failure of birtamimab means no treatment for Mayo Stage IV AL amyloidosis from Prothena.
• Partners (Roche, Novo Nordisk, BMS) benefit from continued collaboration and advancement of partnered programs, indicating ongoing commitment and potential for future milestones/royalties.
• Creditors' risk assessment is influenced by the company's financial health, including its cash balance and burn rate. The exceeding of cash guidance is positive.

Next Steps

• The Annual General Meeting of Shareholders will be held on May 14, 2026, to vote on director elections, auditor ratification, and executive compensation.
• Shane M. Cooke and Dennis J. Selkoe, if elected, will hold office until no later than the annual general meeting in 2029.
• KPMG LLP's appointment as independent auditor for fiscal year 2026 is subject to shareholder ratification.
• Roche's Phase 3 PARAISO clinical trial for prasinezumab is expected to complete in 2029.
• Novo Nordisk's Phase 3 CLEOPATTRA clinical trial for coramitug is expected to complete in 2029.
• Bristol Myers Squibb's Phase 2 TargetTau-1 clinical trial for BMS-986446 is expected to complete in 1H 2027.
• Prothena's Phase 1 clinical trial for PRX019 is on track for completion in 2026.
• Prothena is developing PRX012-TfR in preclinical studies and exploring potential partnership opportunities.
• The Board plans to reduce its size to seven members immediately following the Annual Meeting.
• Shareholder proposals for the 2027 annual meeting must be submitted by November 27, 2026.
• Shareholder director nominations for the 2027 annual meeting must be submitted between October 28, 2026, and December 27, 2026.
• Shareholders intending to solicit proxies for director nominees must provide notice by March 15, 2027.

Key Dates

Recommendation

The significant setback with the birtamimab Phase 3 trial failure and the subsequent large workforce reduction are major negative events that would typically warrant a 'sell' or 'strong sell' recommendation. However, the company's strong cash position, effective cash burn management, and the continued advancement of multiple high-potential partnered programs (prasinezumab, coramitug, BMS-986446, PRX019) provide a counterbalance. The shift of PRX012 to preclinical development and exploration of partnerships, while a downgrade, shows a pragmatic approach. Given the mixed signals, with substantial negatives offset by a solid financial foundation and promising pipeline assets (albeit mostly partnered), a 'hold' recommendation is appropriate for investors to monitor the progress of the partnered programs and the company's ability to execute on its revised strategy. The stock is likely to be volatile, but the long-term potential of the partnered assets prevents a 'sell' at this stage.

Keywords

Prothena, Proxy Statement, Annual General Meeting, Corporate Governance, Executive Compensation, Biotechnology, Neurodegenerative Diseases, Alzheimer's Disease, Parkinson's Disease, ATTR Amyloidosis, Clinical Trials, Drug Development, Birtamimab, PRX012, Prasinezumab, Coramitug, BMS-986446, PRX019, TDP-43 CYTOPE, Workforce Reduction, Cash Management, KPMG LLP, Director Election, Say-on-Pay